The next step in the development of the Chalmers Precision HealthTech Hub is now being taken, with a new laboratory collaboration arena that will be established at GoCo Health Innovation City in Mölndal.
The rapid development of advanced cell and gene therapies, as well as experience from the mRNA vaccines, show the great potential of these new treatments. At the same time, new technologies are needed for the development of mRNA-based drugs.
The purpose of establishing Chalmers Precision HealthTech Hub at GoCo Health Innovation City in Mölndal (which will be completed in 2026), is to offer analysis and development services, infrastructure in the form of equipment and a creative, interdisciplinary meeting place that will contribute to the development of the next generation of medicines. Together with other initiatives in the field, this will give West Sweden increased opportunities for patients to receive qualified care and treatment. At the same time, new companies can be developed, which strengthens the Life Science cluster in the region and nationally.
The planning phase has now been granted support from the Environment and Regional Development Committee in the Västra Götaland region. This means that Chalmers will proceed with the plans for an establishment at GoCo in 2026.
"I am pleased to see how the results of interdisciplinary, long-term and fundamental research will be utilised by offering expertise and services to research, companies and healthcare," says Fredrik Höök, Professor of Biophysics and Director of the FormulaX research centre, which has been conducting method development and research in the field for almost seven years.
"The initiative will also create continued opportunities to conduct high-quality research and method development of the highest relevance to society."
"This is an important step on the way to realising Chalmers Precision HealthTech Hub," says Mats Lundqvist, Vice President for Utilisation. "By developing new technologies linked to mRNA-based drugs, Chalmers can contribute to the safe and precise drugs of the future for the benefit of both patients and West Sweden's Life Science system."
"It is very positive that West Sweden is building a strong cluster of companies and businesses that are driving the development of precision medicine and advanced therapy drugs, ATMPs, forward. Life Science is an area of strength for our region and important for both regional development and healthcare," says Helena Lundberg Nilsson, Regional Development Director, Region Västra Götaland.
Contacts
- Fredrik Höök, Professor of Biophysics, Department of Physics: fredrik.hook@chalmers.se
- Mats Lundqvist, Deputy Vice-Chancellor for Utilisation: mats.lundqvist@chalmers.se
- Bo Norrman, Senior Advisor, Chalmers Area of Advance Health and Technology: bo.norrman@chalmers.se
- Kristina Lagerstedt, Development Manager Chalmers Precision HealthTech Hub: krilage@chalmers.se